Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07XRU
|
|||
| Drug Name |
Telmisartan
|
|||
| Synonyms |
Telmisartan; 144701-48-4; Micardis; Pritor; BIBR 277; Kinzalmono; BIBR-277; BIBR 277SE; Telmisattan; Targit; Telmisartan [INN]; UNII-U5SYW473RQ; BIBR-277SE; BIBR-277-SE; U5SYW473RQ; CHEMBL1017; CHEBI:9434; Telmisartan
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hypertension [ICD-11: BA00-BA04] | Approved | [1] | |
| Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] | Phase 3 | [2] | ||
| Therapeutic Class |
Antiviral Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C33H30N4O2
|
|||
| Canonical SMILES |
CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2C)C5=NC6=CC=CC=C6N5C
|
|||
| InChI |
1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39)
|
|||
| InChIKey |
RMMXLENWKUUMAY-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 144701-48-4
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:9434
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | HUMAN type-1 angiotensin II receptor (AGTR1) | Target Info | Blocker | [3], [4] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 203867. | |||
| REF 2 | ClinicalTrials.gov (NCT04359953) Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19. U.S. National Institutes of Health. | |||
| REF 3 | Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic. Nat Rev Nephrol. 2020 Apr 3. | |||
| REF 4 | Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19. Drug Dev Res. 2020 May 1. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.